Effect of IL-1β and TNF-α polymorphisms on the prognosis and survival of gastric cancer patients.
So far, a number of association studies have focused on the effect of polymorphisms in IL-1β and TNF-α genes on the susceptibility to gastric cancer (GC). Here, we evaluate the possible association between common polymorphisms in the IL-1β and TNF-α genes with various clinicopathological characteristics, including overall survival of GC patients. Restriction fragment length polymorphism analysis was performed for IL-1β-31(T > C) and IL-1β-511(C > T) and TNF-α-857 (C > T) polymorphisms in 130 GC patients. IL-1β-31CC and IL-1β-511TT genotypes held a significantly lower risk of lymphatic invasion (IL-1β-31CC vs. others: adjusted OR = 0.39, 95% CI = 0.15-0.96, P = 0.04, IL-1β-511TT vs. others: adjusted OR = 0.23, 95% CI = 0.08-0.67, P = 0.007). The IL-1β-31CC and IL-1β-511TT genotypes were weakly associated with reduced risk of venous invasion (IL-1β-31CC vs. others: adjusted OR = 0.35, 95% CI = 0.12-1.05, P = 0.06, IL-1β-511TT vs. others: adjusted OR = 0.32, 95% CI = 0.08-1.20, P = 0.09). The IL-1β-511TT genotype was also weakly associated with reduced risk of lymph node metastasis (IL-1β-511TT vs. others: adjusted OR = 0.42, 95% CI = 0.17-1.04, P = 0.06). When the TNF-α-857CT and TNF-α-857-TT genotypes were considered as T carrier, the patients with TNF-α-857T carrier showed significantly better overall survival than patients with CC genotype (P = 0.011). GC patients who have both IL-1β-31 CC and IL-1β-511 TT genotypes and have at least one of protective genotypes (IL-1β-31 CC, IL-1β-511 TT, TNF-α-857 T carrier) were also associated with better prognostic factors, such as lymphatic and venous invasion better survival. IL-1β-31CC, IL-1β-511TT genotype, and TNF-α-857T carrier may have protective effect against GC progression.
Department of Gastroenterology, Fujita Health University School of Medicine, Kutsukake-cho, Toyoake, Aichi, Japan. tomomiccyu@yahoo.co.jp
Tomomitsu
T
Tahara
Tomoyuki
T
Shibata
Masakatsu
M
Nakamura
Hiromi
H
Yamashita
Daisuke
D
Yoshioka
Masaaki
M
Okubo
Joh
J
Yonemura
Yoshiteru
Y
Maeda
Naoko
N
Maruyama
Toshiaki
T
Kamano
Yoshio
Y
Kamiya
Hiroshi
H
Fujita
Yoshihito
Y
Nakagawa
Mitsuo
M
Nagasaka
Masami
M
Iwata
Ichiro
I
Hirata
Tomiyasu
T
Arisawa
D000368:Aged; D005260:Female; D005787:Gene Frequency; D056726:Genetic Association Studies; D005838:Genotype; D006801:Humans; D053583:Interleukin-1beta / Q000235:genetics* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D012150:Polymorphism, Restriction Fragment Length; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D013274:Stomach Neoplasms / Q000235:genetics* / Q000276:immunology / Q000401:mortality*; D016019:Survival Analysis; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics* / Q000276:immunology
D053583:Interleukin-1beta; D014409:Tumor Necrosis Factor-alpha
J Gastroenterol Hepatol. 2007 Jan;22(1):51-9
17201881
Gastroenterology. 2001 Oct;121(4):823-9
11606496
Int J Cancer. 1999 Mar 15;80(6):827-41
10074914
J Clin Periodontol. 2003 Jun;30(6):524-31
12795791
J Natl Cancer Inst. 2002 Nov 20;94(22):1680-7
12441323
Cancer. 1996 Sep 15;78(6):1168-78
8826937
Nature. 2000 Mar 23;404(6776):398-402
10746728
Nat Rev Cancer. 2003 Apr;3(4):276-85
12671666
Oncologist. 2006 Apr;11(4):397-408
16614236
Gut. 2003 Dec;52(12):1684-9
14633943
Gut. 1997 Oct;41(4):442-51
9391240
Acta Pathol Microbiol Scand. 1965;64:31-49
14320675
J Gastroenterol. 1999;34 Suppl 11:10-7
10616759
Tissue Antigens. 1998 Jun;51(6):605-12
9694352
Nature. 2002 Dec 19-26;420(6917):860-7
12490959
J Clin Oncol. 2005 Apr 1;23(10):2339-45
15800325
Gastroenterology. 2002 Dec;123(6):1793-803
12454835
Gastric Cancer. 2000 Dec;3(4):219-225
11984739
Am J Physiol. 1991 Oct;261(4 Pt 1):G559-64
1681735
Clin Cancer Res. 2007 Apr 15;13(8):2422-8
17438101
Br J Cancer. 2006 Dec 4;95(11):1568-75
17088911
Clin Lung Cancer. 2003 Jul;5(1):46-62
14596704